Equities

Hoth Therapeutics Inc

HOTH:NAQ

Hoth Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.98
  • Today's Change-0.03 / -2.97%
  • Shares traded326.26k
  • 1 Year change-40.96%
  • Beta0.7653
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.

  • Revenue in USD (TTM)0.00
  • Net income in USD-7.46m
  • Incorporated2017
  • Employees2.00
  • Location
    Hoth Therapeutics Inc590 Madison Avenue, 21St FloorNEW YORK 10022United StatesUSA
  • Phone+1 (646) 756-2997
  • Websitehttps://hoththerapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Processa Pharmaceuticals Inc0.00-10.22m4.62m13.00--0.6763-----5.36-5.360.002.100.00----0.00-115.58-84.35-133.48-90.03------------0.0016------59.45---34.05--
GT Biopharma Inc0.00-11.35m4.87m2.00--0.8845-----7.72-7.720.002.470.00----0.00-82.84-205.36-120.73--------------0.00------63.62------
CYANOTECH CORP23.82m-5.10m4.87m77.00--0.4563--0.2045-0.7549-0.75493.561.530.88952.0512.12309,389.60-19.04-3.46-29.60-4.4624.7234.54-21.41-3.580.3354-6.610.377---0.4616-5.24-53.11---6.42--
AgriFORCE Growing Systems Ltd57.60k-15.05m4.91m7.00--0.3873--85.17-5.81-5.810.00370.13430.0034--1.218,228.57-88.79-78.95-124.14-109.8617.86---26,121.49-243,182.501.24-1.280.0789------8.85--48.61--
Titan Pharmaceuticals Inc4.00k-5.46m5.17m4.00--1.30--1,293.64-6.59-6.590.00494.370.0016--0.17021,000.00-211.58-96.80-368.99-156.65-----136,525.00-406.26---309.960.00---66.97-51.1645.43---65.61--
Sonnet Biotherapeutics Holdings Inc55.89k-7.99m5.20m12.00--1.99--93.08-3.02-3.020.01440.50170.0071--0.08814,657.50-100.88---255.30-------14,287.67-----331.070.00---57.76--36.64------
Cannapharmarx Inc25.84k627.24k5.83m21.00----8.39225.62-0.0061-0.00610.00006-0.02540.003--0.16541,230.487.36-131.06-----1,692.76--2,427.40--0.0123-0.2483--------143.24------
Integrated BioPharma, Inc.50.57m-116.00k6.77m141.00--0.357831.920.1338-0.0041-0.00411.670.62831.884.4510.76358,617.00-0.43115.54-0.569828.007.0912.09-0.22946.451.02-9.000.001---9.913.00-100.42---14.03--
Coeptis Therapeutics Holdings Inc0.00-16.14m6.97m5.00---------0.5143-0.51430.00-0.01110.00----0.00-284.35-37.29-709.12-38.23------------1.22------43.40------
Hoth Therapeutics Inc0.00-7.46m6.97m2.00--0.5795-----1.69-1.690.001.740.00----0.00-67.99-157.07-76.33-177.32------------0.00------31.01------
Biofrontera Inc35.24m-13.51m7.15m85.00--0.6023--0.2029-5.29-5.2912.122.141.211.977.27414,623.50-46.20---113.24--47.75---38.33--1.46-3.530.0264--18.82---3,045.47------
Bon Natural Life Ltd29.52m4.60m7.20m96.000.36330.061.310.24384.994.9932.1030.230.704515.275.19307,524.6010.8614.0413.6920.6829.9430.0015.4217.622.4130.540.09550.00-1.2922.32-26.3283.09-6.70--
CV Sciences Inc15.85m-2.53m8.31m42.00--3.31--0.5244-0.0157-0.01570.0980.01391.691.5525.35377,285.70-26.94-43.42-73.44-77.7546.0651.81-15.95-45.680.2530--0.0114---1.24-19.80133.96-20.87----
Bioquest Corp0.00-507.41k8.61m-----------0.0485-0.04850.00-0.04670.00-------3,483.76-----------------3.88--------64.67------
Data as of Sep 19 2024. Currency figures normalised to Hoth Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

5.05%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 30 Jun 2024213.00k3.09%
UBS Securities LLCas of 30 Jun 202441.21k0.60%
The Vanguard Group, Inc.as of 30 Jun 202438.80k0.56%
Geode Capital Management LLCas of 30 Jun 202435.66k0.52%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 202410.01k0.15%
Tower Research Capital LLCas of 30 Jun 20247.53k0.11%
UBS Financial Services, Inc.as of 30 Jun 20242.15k0.03%
Brewin Dolphin Wealth Management Ltd.as of 30 Jun 2024240.000.00%
Qube Research & Technologies Ltd.as of 30 Jun 2024100.000.00%
Bank of America, NA (Private Banking)as of 30 Jun 202435.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.